1937 Alfa Romeo 8C 2900B Berlinetta Named the Most Prestigious Car in the World
8.2.2019 12:06:00 EET | Business Wire | Press release
Arguably one of the most desirable cars of all time, the remarkable 1937 Alfa Romeo 8C 2900B Berlinetta today was revealed at The Peninsula Paris hotel as the winner of the fourth annual The Peninsula Classics Best of the Best Award.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190208005130/en/
The 1937 ALFA ROMEO 8C 2900B BERLINETTA was named winner of The Peninsula Classics Best of the Best Award. (Photo: Jana Call me J)
While eight stunning ‘Best of Show’ winners from top concours around the world competed for the accolade, the Alfa Romeo was the stand-out choice among the judges as the best car in the world. Hailing from Los Angeles, California, the car was entered into the running for the award after being named ‘Best of Show’ at the 2018 Pebble Beach Concours d’Elegance.
“The winning Alfa Romeo is a perfect example of the type of car that inspired us to create this award,” said William E. (Chip) Connor, Chairman and CEO of William E. Connor & Associates Ltd, and co-founder of The Peninsula Classics Best of the Best Award. “To provide an opportunity for car lovers to pause a moment and celebrate flawless design and engineering of this calibre is truly an honour each year.”
The Alfa Romeo is owned by David and Ginny Sydorick of Los Angeles, California. Reflecting on the car’s recent recognition, David said: “As an avid auto-collector, having two cars in the running for this year’s award was truly remarkable. It goes without saying that Ginny and I are ecstatic at the result – a proud moment for us both.”
The winning car was unveiled using a ‘shutter-effect’, whereby individual slats turned in sync to reveal the Alfa Romeo standing proudly within a bespoke-designed, up-lit box. Following the big reveal, guests at the party, including ‘Beauty and the Beast,’ ‘The Alienist,’ and ‘Girl on a Train’ star Luke Evans, were further treated to a music set from notable DJ and On-Camera Personality, Hannah Bronfman, who was joined by husband, DJ and Entrepreneur, Brendan Fallis.
An automotive jewel engineered by Ingegner Vittorio Jano, the 8C 2900 was designed to compete in sports car races, specifically the Mille Miglia, which it won outright in 1935, 1936, 1937, 1938 and 1947. In racing trim, they dominated all the major competitions, and in road trim, they were the fastest grand touring cars.
Established in 1925 in Milan, Italian coachbuilder Carrozzeria Touring had first licensed Charles Weymann's system of fabric-covered lightweight frames and then developed its own ‘Superleggera’ construction. Patented in 1936, the Superleggera system consists of a structural framework of small-diameter steel tubes that conform to an automobile body's shape and are covered by thin alloy body panels that strengthen the framework. The winning vehicle, 412020, is the first of only five known Berlinettas built on the Lungo chassis and is the car that Touring refers to as the beginning of Superleggera.
About The Peninsula Classics Best of the Best Award
Through a shared desire to celebrate the best of what defines the automotive world, The Hon. Sir Michael Kadoorie, Chairman of The Hongkong and Shanghai Hotels, Limited, launched The Peninsula Classics Best of the Best Award in 2015 with co-founders William E. (Chip) Connor, Bruce Meyer and Christian Philippsen. Each founder shares a common passion and appreciation of fine motor cars, the preservation of their heritage and immaculate restoration projects. The award, sponsored by The Peninsula Hotels, brings together eight of the concours circuits’ elite ‘Best of Show’ winners from around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190208005130/en/
Contact information
Media:
Sanaz Marbley/Devon Zahm
JMPR Public Relations
+1
(818) 992 4353
smarbley@jmpr.com
/ dzahm@jmpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom